Podcast 294: PD-1 blockade in locally advanced rectal cancer
Locally advanced rectal cancer usually receives a three-part treatment: chemotherapy followed by radiotherapy and then surgery. In a small-cohort study presented at this year’s ASCO conference researchers used a PD-1 inhibitor — dostarlimab — every three weeks for 6 months against the disease. All patients had mismatch repair deficient tumors. No other treatments were needed however, […]
The post Podcast 294: PD-1 blockade in locally advanced rectal cancer first appeared on Clinical Conversations.